Cubist_Pharmaceuticals
Cubist Pharmaceuticals
Defunct American pharmaceutical company
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.
| Company type | Subsidiary (formerly: Public) |
|---|---|
| Nasdaq: CBST | |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992 |
| Defunct | 2015 |
| Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez, President, CEO; |
| Products | Product Pipeline |
| Revenue |  $926.4 million USD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
.[1] The company employed 638 people, mostly in Lexington, MA.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]
Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.[5]
In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.[6]
The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.
In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.[7]
In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.[8]
In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.
The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.[9] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).[10]
In 2011, its product pipeline focused on gram-negative bacterial infections,[11] Clostridium difficile-associated diarrhea,[12] and respiratory syncytial virus.[13]
Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.[14][15]
- Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.
- "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.
- Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014
- "SEC Form S3 Cubist Pharmaceuticals, Inc". March 8, 2000.
- "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.
- "Cubist Profit Down 53%", Drug Discovery & Development, Advantage Business Media, 19 Jan 2012, retrieved 22 Jan 2012
{{citation}}: Unknown parameter|agency=ignored (help) - Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
- Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.
- "Cubist Settles Teva Patent Litigation on Antibiotic Cubicin". Bloomberg. 2011-04-05. Retrieved 28 May 2011.
- "Optimer to Market Dificid Drug With Cubist Pharmaceuticals". Bloomberg. 2011-04-06.
- Donnelly, Julie M. (13 December 2011). "Cubist advances antibiotic for Gram-negative bacteria". www.bizjournals.com. Retrieved 2017-10-31.
- Brown, Rodney H. (6 April 2011). "Cubist – Optimer diarrhea drug could net $47M". www.bizjournals.com. Retrieved 2017-10-31.
- "Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs". GenomeWeb. Retrieved 2017-10-31.
- Michael r. Page, Pharmd (17 September 2014). "Sivextro by Cubist Pharmaceuticals". www.pharmacytimes.com. September 2014. 3 (5). Retrieved 2017-10-31.
- "Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review | FierceBiotech". www.fiercebiotech.com. 30 December 2013. Retrieved 2017-10-31.